Novo Nordisk Regains Traction as Oral Wegovy Strengthens Position Against Lilly
Novo Nordisk has begun to claw back after a difficult stretch, buoyed by stronger-than-expected demand for its oral Wegovy pill. The rebound comes amid an intensifying rivalry with Eli Lilly, where injectables and new pills are reshaping market dynamics in an obesity treatment market estimated to exceed $100 billion in the United States by the end …